News
RGNX
7.18
-1.10%
-0.08
Stocks to Watch for Wednesday: TJX, TTWO, TGT & more
Seeking Alpha · 1d ago
Capricor, Regenxbio among gainers as White House pulls Trump’s FDA pick
Seeking Alpha · 1d ago
Weekly Report: what happened at RGNX last week (1109-1113)?
Weekly Report · 3d ago
REGENXBIO Earnings Call Signals Progress Toward Gene Therapy Launch
TipRanks · 4d ago
News Flash: Analysts Just Made A Notable Upgrade To Their REGENXBIO Inc. (NASDAQ:RGNX) Forecasts
Simply Wall St · 11/11 10:24
Weekly Report: what happened at RGNX last week (1102-1106)?
Weekly Report · 11/09 09:34
REGENXBIO Inc. (NASDAQ:RGNX) Analysts Are Pretty Bullish On The Stock After Recent Results
Simply Wall St · 11/08 13:16
Regenxbio: 2 Major Catalysts Could Change The Investment Case
Seeking Alpha · 11/06 18:19
REGENXBIO: Buy Rating Maintained with $21 Price Target Unchanged on Sura-Vec and RGX-202 Catalysts
TipRanks · 11/06 13:58
Regenxbio price target lowered to $14 from $15 at BofA
TipRanks · 11/06 13:05
Bank of America Securities Reaffirms Their Buy Rating on RegenXBio (RGNX)
TipRanks · 11/06 12:58
Regenxbio price target lowered to $18 from $19 at Mizuho
TipRanks · 11/06 12:40
Regenxbio price target lowered to $25 from $29 at Baird
TipRanks · 11/06 11:52
Analysts Offer Insights on Healthcare Companies: Astrana Health (ASTH) and RegenXBio (RGNX)
TipRanks · 11/06 09:20
REGENXBIO Inc. Reports Third Quarter 2026 Financial Results and Program Milestones
NASDAQ · 11/05 21:53
REGENXBIO (RGNX) Q3 2026 Earnings Call Transcript
The Motley Fool · 11/05 19:33
Democrats Sweep Midterms: What It Means For Pharma And Biotech Holdings (Stocks To Watch)
Seeking Alpha · 11/05 17:09
Regenxbio Q3 2026 Earnings Call Transcript
Benzinga · 11/05 14:14
Regenxbio Inc Q3 Loss Drops
NASDAQ · 11/05 12:20
Press Release: REGENXBIO Reports Third Quarter 2026 Financial Results and Operational Highlights
Dow Jones · 11/05 12:05
More
Webull provides a variety of real-time RGNX stock news. You can receive the latest news about Regenxbio through multiple platforms. This information may help you make smarter investment decisions.
About RGNX
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address an array of diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). It is developing RGX-121 for the treatment of Mucopolysaccharidosis type II (MPS II), and RGX-111 to treat Mucopolysaccharidosis Type I.